SAJA is a joint venture between the premier Saudi healthcare company Tamer Industries and two of the leading Japanese Pharmaceutical companies which are Daiichi Sankyo Company Ltd and Astellas Pharma Inc.
With extended arms and on behalf of SAJA’s Family, I would like to welcome you in SAJA Pharmaceutical platform.
We as an organization stand out in the midst of the uncertainty of global situation with sustainable momentum and passion to success. Through the years we have managed to unlock many possibilities towards our vision to establish and grow a trusted name in the pharmaceutical industry under the umbrella of Tamer group.
Our deeply rooted core values drive our growth, success and professional alignments. we also take pride in our collaboration with our
partners and licensors companies to advocate our strategy.
May all who enter as a guest become a valuable addition to our team and business. Therefore, I would like to encourage you to unlock
your potentials and explore our opportunities where you will master embracing and overcoming all the arising challenges during the
journey.
SAJA CEO
SAJA was established in 1996 and introduced the first product to Saudi market in 2000. Since then, SAJA is expanding geographically and diversifying its unique portfolio
Foundation as a partnership between Tamer, Yamanouchi & Sankyo
1st production
Expansion to GCC & Production of SAJA generics
Restructuring and rebranding of the partnership with the established organizations
SAJA Expansion project
Establishment of diabetes line in partnership with Sanofi and Novartis
Acquisition of SAJA Egypt “formerly Biopharm scientific & research”
Establishment OTX products Like Alamax, Lactoglobin, and NEM OTX: OTC & Rx products
Agreement with Xellia to start Critical Hospital care products
